Loading patent…
AssigneeAmine Pharma Research Institute Co., Ltd.
InventorsKazuei Igarashi, Keiko Kashiwagi, Madoka Yoshida, Mutsumi Mizoi, Ryotaro Saiki
Estimating the term…
Provided is a novel assessment method for stroke and cerebral infarction (in particular, asymptomatic cerebral infarction) without any burden on a subject to be tested. It is newly found that the content of 3-HPMA, which is a metabolite of acrolein, in a urine specimen decreases in a stroke patient as compared to a healthy subject without history of stroke, irrespective of smoking habits and gender, which is quite different from the result expected from a conventional finding. Thus, an assessment method for stroke and/or cerebral infarction, including using 3-HPMA in a urine specimen as an indicator, is completed.
An assessment method for stroke and/or cerebral infarction, comprising using, as an indicator, that a content of 3-hydroxypropyl mercapturic acid (3-HPMA) in a urine specimen obtained from a subject to be tested is low as compared to that of a healthy subject.
An assessment method for stroke and/or cerebral infarction, comprising using, as an indicator, that a content of 3-HPMA in a urine specimen obtained from a subject to be tested is low as compared to that of a healthy subject,
An assessment kit for stroke and/or cerebral infarction, comprising a reagent for measuring a content of 3-HPMA in a urine specimen.
Dependencies are inferred from the claim text.